STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

  1. Home
  2. News
  3. Clinical Trials

Clinical Trials News LIVE

Step into the labs where medical history is made. Our clinical trial news feed brings you to the forefront of scientific discovery and its market implications.

Each trial result is a potential game-changer. Whether it's a Phase 3 triumph or an unexpected study termination, we've got you covered.

Don't just follow biotech trends – anticipate them. With our real-time clinical trial updates, you're positioned to react to scientific progress as it happens, potentially before the broader market catches on.

3

NEWS
TODAY
check them out

-

NEWS ENHANCED BY
RHEA-AI
Who is Rhea? Read More
NEWS BY EXCHANGE
NYSE Nasdaq OTC

Stock News Live Feed

Today's News - Full List
No News Found

No news articles match your current filters.

Try adjusting your filter settings or check back later.

IMPACT
SENTIMENT
TLSA : Nasdaq
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
clinical trial penny stock
IMPACT
SENTIMENT
MLYS : Nasdaq
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
clinical trial
IMPACT
SENTIMENT
RCUS : NYSE
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
clinical trial
IMPACT
SENTIMENT
SAGMF : OTC
SAGA Metals Completes Phase 2 of Major Drill Program at the Radar Project in Labrador—Confirms Extensive Oxide Mineralization in All Drill Locations at Trapper North and South Zones & Provides Corporate Update
clinical trial penny stock
IMPACT
SENTIMENT
BYSI : Nasdaq
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
clinical trial
IMPACT
SENTIMENT
INVA : Nasdaq
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
clinical trial
IMPACT
SENTIMENT
ANIX : Nasdaq
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
clinical trial
IMPACT
SENTIMENT
TNYA : Nasdaq
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
clinical trial penny stock
IMPACT
SENTIMENT
TNYA : Nasdaq
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
clinical trial penny stock
IMPACT
SENTIMENT
CELC : Nasdaq
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
clinical trial
IMPACT
SENTIMENT
MAIA : NYSE
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
clinical trial penny stock
IMPACT
SENTIMENT
ILMN : Nasdaq
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
clinical trial
IMPACT
SENTIMENT
MAIA : NYSE
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
clinical trial penny stock
IMPACT
SENTIMENT
RNXT : Nasdaq
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
clinical trial penny stock
IMPACT
SENTIMENT
OKYO : Nasdaq
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
clinical trial
IMPACT
SENTIMENT
AINMF : OTC
NetraMark Continues Expansion Into Phase 3 Programs With Contract From Global Biopharmaceutical Company
clinical trial penny stock
IMPACT
SENTIMENT
PFSA : Nasdaq
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026
clinical trial penny stock
IMPACT
SENTIMENT
CVKD : Nasdaq
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
acquisition clinical trial low float
IMPACT
SENTIMENT
RNAZ : Nasdaq
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
clinical trial low float
IMPACT
SENTIMENT
ELTX : Nasdaq
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
clinical trial low float
IMPACT
SENTIMENT
ACN : NYSE
Accenture Invests in Ryght AI to Help Life Sciences Companies Transform Clinical Research with Agentic AI
clinical trial AI
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
clinical trial
IMPACT
SENTIMENT
BYSI : Nasdaq
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
clinical trial
IMPACT
SENTIMENT
RZLT : Nasdaq
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
clinical trial penny stock
IMPACT
SENTIMENT
ACIU : Nasdaq
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
clinical trial
IMPACT
SENTIMENT
KYMR : Nasdaq
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
clinical trial
IMPACT
SENTIMENT
BHVN : NYSE
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
clinical trial
IMPACT
SENTIMENT
LLY : NYSE
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
clinical trial
IMPACT
SENTIMENT
NKGFF : OTC
NEVADA KING ANNOUNCES FULLY FUNDED 20,000M, PHASE 4 EXPLORATION PROGRAM DESIGNED TO ADVANCE MULTIPLE REGIONAL TARGETS IDENTIFIED IN PHASE 3
clinical trial penny stock
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
clinical trial
IMPACT
SENTIMENT
NTRA : Nasdaq
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
clinical trial
IMPACT
SENTIMENT
NBP : Nasdaq
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
clinical trial
IMPACT
SENTIMENT
AARD : Nasdaq
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
clinical trial low float
IMPACT
SENTIMENT
GRI : Nasdaq
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 
clinical trial low float penny stock
IMPACT
SENTIMENT
QNCX : Nasdaq
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
clinical trial
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
clinical trial
IMPACT
SENTIMENT
IGC : NYSE
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
clinical trial penny stock
IMPACT
SENTIMENT
DERM : Nasdaq FBIO : Nasdaq
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
clinical trial
IMPACT
SENTIMENT
AUID : Nasdaq
authID’s PrivacyKey™ Named “Best Digital Trust Solution - ID Verification & Authentication” in 2025 PayTech Awards
IMPACT
SENTIMENT
BRNS : Nasdaq
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
clinical trial penny stock
IMPACT
SENTIMENT
COCH : Nasdaq
Envoy Medical Completes First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant
clinical trial low float penny stock
IMPACT
SENTIMENT
BCTX : Nasdaq BCTXW : Nasdaq BCTXZ : Nasdaq
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
clinical trial low float penny stock
IMPACT
SENTIMENT
MDNAF : OTC
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
clinical trial penny stock
IMPACT
SENTIMENT
SGMT : Nasdaq
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
clinical trial
IMPACT
SENTIMENT
MDWD : Nasdaq
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
clinical trial low float
IMPACT
SENTIMENT
BEAT : Nasdaq
HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment
clinical trial fda approval
IMPACT
SENTIMENT
SGMT : Nasdaq
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
clinical trial
IMPACT
SENTIMENT
MDNAF : OTC
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
clinical trial penny stock
IMPACT
SENTIMENT
IGC : NYSE
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
clinical trial penny stock
IMPACT
SENTIMENT
PTIX : Nasdaq
Results from Phase 1 Multiple-Dose Study of PT00114
clinical trial low float penny stock
Today's News - Full List